Dae Gon Ha
Stock Analyst at Stifel
(2.38)
# 2,497
Out of 5,165 analysts
55
Total ratings
35.56%
Success rate
4.06%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $98 → $125 | $92.64 | +34.93% | 6 | Feb 26, 2026 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $4.95 | +304.04% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.54 | +18.11% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $33.39 | +121.62% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $7.44 | -59.68% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $13.38 | +378.33% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $250.16 | -12.06% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $21.82 | +482.03% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $4.87 | +885.63% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.67 | +390.46% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $2.32 | +201.72% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.17 | +411.31% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $90.51 | -72.38% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.37 | +11.34% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $25.50 | +1,017.65% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.76 | +1,036.36% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.51 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $18.87 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.30 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.91 | +1,218.68% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $20.23 | +2,322.15% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $125
Current: $92.64
Upside: +34.93%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $4.95
Upside: +304.04%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.54
Upside: +18.11%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $33.39
Upside: +121.62%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $7.44
Upside: -59.68%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $13.38
Upside: +378.33%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $250.16
Upside: -12.06%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $21.82
Upside: +482.03%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $4.87
Upside: +885.63%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.67
Upside: +390.46%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $2.32
Upside: +201.72%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.17
Upside: +411.31%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $90.51
Upside: -72.38%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.37
Upside: +11.34%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $25.50
Upside: +1,017.65%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.76
Upside: +1,036.36%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.51
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $18.87
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $9.30
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.91
Upside: +1,218.68%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $20.23
Upside: +2,322.15%